Liver Cirrhosis – Pipeline Review, H1 2012
Reference Code: GMDHC1843IDB
Publication Date: April 2012
Liver Cirrhosis – Pipeline Review, H1 2012 GMDHC1843IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1)
Liver Cirrhosis – Pipeline Review, H1 2012
Table of Contents
Table of Contents ............................................................................................................................................................................... 2
List of Tables ................................................................................................................................................................................. 5
List of Figures ................................................................................................................................................................................ 5
Introduction......................................................................................................................................................................................... 6
Global Markets Direct Report Coverage ........................................................................................................................................ 6
Liver Cirrhosis Overview..................................................................................................................................................................... 7
Therapeutics Development................................................................................................................................................................. 8
An Overview of Pipeline Products for Liver Cirrhosis .................................................................................................................... 8
Liver Cirrhosis Therapeutics under Development by Companies ..................................................................................................... 10
Liver Cirrhosis Therapeutics under Investigation by Universities/Institutes ...................................................................................... 11
Late Stage Products ......................................................................................................................................................................... 13
Comparative Analysis .................................................................................................................................................................. 13
Mid Clinical Stage Products.............................................................................................................................................................. 14
Comparative Analysis .................................................................................................................................................................. 14
Early Clinical Stage Products ........................................................................................................................................................... 15
Comparative Analysis .................................................................................................................................................................. 15
Pre-Clinical Stage Products.............................................................................................................................................................. 16
Comparative Analysis .................................................................................................................................................................. 16
Liver Cirrhosis Therapeutics – Products under Development by Companies ................................................................................... 17
Liver Cirrhosis Therapeutics – Products under Investigation by Universities/Institutes .................................................................... 18
Companies Involved in Liver Cirrhosis Therapeutics Development.................................................................................................. 19
Stelic Institute & Co. .................................................................................................................................................................... 19
Stempeutics Research Private Limited ........................................................................................................................................ 20
Liver Cirrhosis – Therapeutics Assessment ..................................................................................................................................... 21
Assessment by Monotherapy Products ....................................................................................................................................... 21
Assessment by Combination Products ........................................................................................................................................ 22
Assessment by Route of Administration ...................................................................................................................................... 23
Assessment by Molecule Type .................................................................................................................................................... 25
Drug Profiles..................................................................................................................................................................................... 27
STNM04 - Drug Profile ................................................................................................................................................................ 27
Product Description................................................................................................................................................................. 27
Mechanism of Action ............................................................................................................................................................... 27
R&D Progress ......................................................................................................................................................................... 27
Sorafenib - Drug Profile ............................................................................................................................................................... 28
Product Description................................................................................................................................................................. 28
Mechanism of Action ............................................................................................................................................................... 28
R&D Progress ......................................................................................................................................................................... 28
Autologous CD133 + Stem Cells - Drug Profile ........................................................................................................................... 30
Product Description................................................................................................................................................................. 30
Mechanism of Action ............................................................................................................................................................... 30
R&D Progress ......................................................................................................................................................................... 30
Torisel - Drug Profile.................................................................................................................................................................... 31
Liver Cirrhosis – Pipeline Review, H1 2012 GMDHC1843IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2)
Liver Cirrhosis – Pipeline Review, H1 2012
Product Description................................................................................................................................................................. 31
Mechanism of Action ............................................................................................................................................................... 31
R&D Progress ......................................................................................................................................................................... 31
Lenograstim + Haematopoietic Stem Cells - Drug Profile............................................................................................................ 32
Product Description................................................................................................................................................................. 32
Mechanism of Action ............................................................................................................................................................... 32
R&D Progress ......................................................................................................................................................................... 32
Nobelzin - Drug Profile ................................................................................................................................................................ 33
Product Description................................................................................................................................................................. 33
Mechanism of Action ............................................................................................................................................................... 33
R&D Progress ......................................................................................................................................................................... 33
Bone Marrow Derived CD133+ Stem Cells Transplantation - Drug Profile .................................................................................. 34
Product Description................................................................................................................................................................. 34
Mechanism of Action ............................................................................................................................................................... 34
R&D Progress ......................................................................................................................................................................... 34
Umbilical Cord Mesenchymal Stem Cells - Drug Profile .............................................................................................................. 35
Product Description................................................................................................................................................................. 35
Mechanism of Action ............................................................................................................................................................... 35
R&D Progress ......................................................................................................................................................................... 35
Allogenic Bone Marrow Stem Cells Transplant - Drug Profile ..................................................................................................... 36
Product Description................................................................................................................................................................. 36
Mechanism of Action ............................................................................................................................................................... 36
R&D Progress ......................................................................................................................................................................... 36
Autologous Bone Marrow Mesenchymal Stem Cells Transplant - Drug Profile ........................................................................... 37
Product Description................................................................................................................................................................. 37
Mechanism of Action ............................................................................................................................................................... 37
R&D Progress ......................................................................................................................................................................... 37
Umbilical Cord Mesenchymal Stem Cells - Drug Profile .............................................................................................................. 38
Product Description...